285 related articles for article (PubMed ID: 28960861)
1. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
Li YQ; Liu YS; Ying XW; Zhou HB; Wang Z; Wu SC; Yan JP; Jing YT; Yang Y
Biotechnol Prog; 2018 Jan; 34(1):196-205. PubMed ID: 28960861
[TBL] [Abstract][Full Text] [Related]
2. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
3. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.
Cui Z; Liu Z; Zeng J; Zhang S; Chen L; Zhang G; Xu W; Song L; Guo X
Life Sci; 2019 May; 224():23-32. PubMed ID: 30902544
[TBL] [Abstract][Full Text] [Related]
4. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
[TBL] [Abstract][Full Text] [Related]
5. Lentivirus-mediated ADAM17 RNA interference inhibited interleukin-8 expression via EGFR signaling in lung epithelial cells.
Li Y; Yan J; Xu W; Wang H; Xia Y
Inflammation; 2012 Jun; 35(3):850-8. PubMed ID: 21932060
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma.
Liu Y; Jiang H; Zhou H; Ying X; Wang Z; Yang Y; Xu W; He X; Li Y
Oncol Lett; 2018 Mar; 15(3):2829-2838. PubMed ID: 29467862
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
8. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
10. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M
Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786
[TBL] [Abstract][Full Text] [Related]
11. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
13. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
14. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
17. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
Wang T; Liu Z; She Y; Deng J; Zhong Y; Zhao M; Li S; Xie D; Sun X; Hu X; Chen C
Cancer Lett; 2021 Nov; 520():321-331. PubMed ID: 34389432
[TBL] [Abstract][Full Text] [Related]
18. PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells.
Kim TW; Ryu HH; Li SY; Li CH; Lim SH; Jang WY; Jung S
J Neurosurg; 2017 Jun; 126(6):1829-1838. PubMed ID: 27540907
[TBL] [Abstract][Full Text] [Related]
19. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
20. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
